{"entity": "researcher", "timestamp": "2026-08-28T00:12:18.852Z", "family": "Ehinger", "given": "Erik", "initials": "E", "orcid": "0000-0002-1861-5631", "affiliations": ["Neurosurgery, Department of Clinical Sciences, Lund University, Sk\u00e5ne University Hospital, Lund, Sweden. erik.ehinger@med.lu.se.", "Glioma Immunotherapy Group, Neurosurgery, Department of Clinical Sciences, Lund University, Lund, Sweden. erik.ehinger@med.lu.se."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/55255b47f9114bfe888ea7b3143814de.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/55255b47f9114bfe888ea7b3143814de"}}, "publications": [{"entity": "publication", "iuid": "61ee2dbc777744079e5c0be7eb63a815", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/61ee2dbc777744079e5c0be7eb63a815.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/61ee2dbc777744079e5c0be7eb63a815"}}, "title": "Antisecretory factor as add-on treatment for newly diagnosed glioblastoma, IDH wildtype: study protocol for a randomized double-blind placebo-controlled trial.", "authors": [{"family": "Ehinger", "given": "Erik", "initials": "E", "orcid": "0000-0002-1861-5631", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/55255b47f9114bfe888ea7b3143814de.json"}}, {"family": "Darabi", "given": "Anna", "initials": "A"}, {"family": "Visse", "given": "Edward", "initials": "E"}, {"family": "Edvardsson", "given": "Charlotte", "initials": "C"}, {"family": "Tomasevic", "given": "Gregor", "initials": "G"}, {"family": "Cederberg", "given": "David", "initials": "D"}, {"family": "Kinhult", "given": "Sara", "initials": "S"}, {"family": "Rydelius", "given": "Anna", "initials": "A"}, {"family": "Nilsson", "given": "Christer", "initials": "C"}, {"family": "Belting", "given": "Mattias", "initials": "M"}, {"family": "Bengzon", "given": "Johan", "initials": "J"}, {"family": "Siesj\u00f6", "given": "Peter", "initials": "P"}], "type": "journal article", "published": "2025-03-13", "journal": {"title": "Trials", "issn": "1745-6215", "volume": "26", "issue": "1", "pages": "86", "issn-l": null}, "abstract": "Glioblastoma, IDH wildtype is the most common primary malignant brain tumor in adults. Despite best available treatment, prognosis remains poor. Current standard therapy consists of surgical tumor removal followed by radiotherapy and chemotherapy with the alkylating agent temozolomide. Antisecretory factor (AF), an endogenous protein, may potentiate the effect of temozolomide and alleviate cerebral edema. Salovum\u00ae is an egg-yolk powder enriched for AF and is classified as a medical food in the European Union. Salovum\u00ae has shown preliminary clinical effect on glioblastoma in a recent pilot study. Here, we aim to assess if add-on Salovum\u00ae to temozolomide therapy can improve outcomes in patients with newly diagnosed glioblastoma.\n\nThis is a multi-center, double-blinded, randomized, placebo-controlled phase II-III clinical trial to investigate superiority of Salovum\u00ae over placebo as add-on treatment for glioblastoma during concomitant and adjuvant temozolomide therapy. Patients with newly diagnosed glioblastoma that are planned for temozolomide treatment are screened for eligibility and randomized to receive Salovum\u00ae (n = 150) or placebo (n = 150). An interim analysis will be performed after 80 included patients to guide whether to continue or terminate. Primary endpoint is 12-month overall survival. Secondary outcome is 24-month overall survival.\n\nThis study will likely produce high-grade evidence to support or reject Salovum\u00ae as add-on treatment for glioblastoma.\n\nClinicalTrials.gov NCT05669820 . Registered on January 3, 2023.", "doi": "10.1186/s13063-025-08792-z", "pmid": "40083039", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC11905463"}, {"db": "pii", "key": "10.1186/s13063-025-08792-z"}, {"db": "ClinicalTrials.gov", "key": "NCT05669820"}], "notes": [], "created": "2026-08-21T12:40:25.231Z", "modified": "2026-08-21T12:40:25.299Z"}, {"entity": "publication", "iuid": "7e67484215fd4daba989ebb00f7c496a", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/7e67484215fd4daba989ebb00f7c496a.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/7e67484215fd4daba989ebb00f7c496a"}}, "title": "Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma.", "authors": [{"family": "Ehinger", "given": "Erik", "initials": "E", "orcid": "0000-0002-1861-5631", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/55255b47f9114bfe888ea7b3143814de.json"}}, {"family": "Kopecky", "given": "Jan", "initials": "J"}, {"family": "Darabi", "given": "Anna", "initials": "A"}, {"family": "Visse", "given": "Edward", "initials": "E"}, {"family": "Edvardsson", "given": "Charlotte", "initials": "C"}, {"family": "Tomasevic", "given": "Gregor", "initials": "G"}, {"family": "Cederberg", "given": "David", "initials": "D"}, {"family": "Belting", "given": "Mattias", "initials": "M"}, {"family": "Bengzon", "given": "Johan", "initials": "J"}, {"family": "Siesj\u00f6", "given": "Peter", "initials": "P"}], "type": "journal article", "published": "2023-02-18", "journal": {"title": "BMC Neurol", "issn": "1471-2377", "volume": "23", "issue": "1", "pages": "76", "issn-l": null}, "abstract": "Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Despite the best available treatment, prognosis remains poor. Current standard therapy consists of surgical removal of the tumor followed by radiotherapy and chemotherapy with the alkylating agent temozolomide (TMZ). Experimental studies suggest that antisecretory factor (AF), an endogenous protein with proposed antisecretory and anti-inflammatory properties, may potentiate the effect of TMZ and alleviate cerebral edema. Salovum is an egg yolk powder enriched for AF and is classified as a medical food in the European Union. In this pilot study, we evaluate the safety and feasibility of add-on Salovum in GBM patients.\n\nEight patients with newly diagnosed, histologically confirmed GBM were prescribed Salovum during concomitant radiochemotherapy. Safety was determined by the number of treatment-related adverse events. Feasibility was determined by the number of patients who completed the full prescribed Salovum treatment.\n\nNo serious treatment-related adverse events were observed. Out of 8 included patients, 2 did not complete the full treatment. Only one of the dropouts was due to issues directly related to Salovum, which were nausea and loss of appetite. Median survival was 23 months.\n\nWe conclude that Salovum is safe to use as an add-on treatment for GBM. In terms of feasibility, adherence to the treatment regimen requires a determined and independent patient as the large doses prescribed may cause nausea and loss of appetite.\n\nClinicalTrials.gov NCT04116138. Registered on 04/10/2019.", "doi": "10.1186/s12883-023-03119-4", "pmid": "36803465", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC9938624"}, {"db": "pii", "key": "10.1186/s12883-023-03119-4"}, {"db": "ClinicalTrials.gov", "key": "NCT04116138"}], "notes": [], "created": "2026-08-21T12:38:38.806Z", "modified": "2026-08-21T12:38:38.932Z"}]}